How does Leqembi, the first Alzheimer’s drug to slow disease progression, work?

US FDA has granted final approval to anti-Alzheimer's drug lecanemab, marked as Leqembi. In a trial, it slowed down the progression of Alzheimer's and reduced the amount of a material called amyloid beta that builds up in the brains of people with Alzheimer's disease. It does not reverse brain damage caused by Alzheimer's or stop it from getting worse.